$KZR
 
Kezar Life Sciences, Inc. (NASDAQ: KZR), a clinical-stage biotechnology company, reported positive top-line results from the Phase 2 clinical trial named MISSION, evaluating zetomipzomib, a novel, first-in-class selective immunoproteasome inhibitor, in patients with active lupus nephritis (LN).
 
The Company made a solid comeback after a setback in May 2022, when top-line results from a Phase 2 study showed that the candidate failed to beat a placebo in a trial evaluating zetomipzomib as a treatment for dermatomyositis or polymyositis.
 

https://www.aviseanalytics.com/kezar-makes-a-solid-comeback/